VALBIOTIS SA (ALVAL.PA) Stock Fundamental Analysis
EPA:ALVAL - Euronext Paris - Matif - FR0013254851 - Common Stock - Currency: EUR
We assign a fundamental rating of 2 out of 10 to ALVAL. ALVAL was compared to 73 industry peers in the Biotechnology industry. While ALVAL seems to be doing ok healthwise, there are quite some concerns on its profitability. ALVAL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ALVAL has reported negative net income.
In the past year ALVAL has reported a negative cash flow from operations.
In the past 5 years ALVAL always reported negative net income.
ALVAL had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
ALVAL has a Return On Assets of -51.13%. This is in the lower half of the industry: ALVAL underperforms 63.01% of its industry peers.
ALVAL has a Return On Equity (-96.69%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.13% | ||
| ROE | -96.69% | ||
| ROIC | N/A |
ROA(3y)-39.5%
ROA(5y)-33.42%
ROE(3y)-75.49%
ROE(5y)-68.14%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ALVAL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALVAL does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALVAL has about the same amout of shares outstanding than it did 1 year ago.
ALVAL has more shares outstanding than it did 5 years ago.
ALVAL has a worse debt/assets ratio than last year.
2.2 Solvency
ALVAL has an Altman-Z score of 1.44. This is a bad value and indicates that ALVAL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ALVAL (1.44) is comparable to the rest of the industry.
ALVAL has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
ALVAL has a Debt to Equity ratio of 0.34. This is comparable to the rest of the industry: ALVAL outperforms 52.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.44 |
ROIC/WACCN/A
WACC7.07%
2.3 Liquidity
A Current Ratio of 3.04 indicates that ALVAL has no problem at all paying its short term obligations.
ALVAL has a Current ratio of 3.04. This is in the better half of the industry: ALVAL outperforms 64.38% of its industry peers.
A Quick Ratio of 2.66 indicates that ALVAL has no problem at all paying its short term obligations.
ALVAL has a better Quick ratio (2.66) than 64.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.04 | ||
| Quick Ratio | 2.66 |
3. Growth
3.1 Past
The earnings per share for ALVAL have decreased by -6.43% in the last year.
The Revenue for ALVAL has decreased by -96.30% in the past year. This is quite bad
The Revenue has been growing by 13.97% on average over the past years. This is quite good.
EPS 1Y (TTM)-6.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.15%
Revenue 1Y (TTM)-96.3%
Revenue growth 3Y-16.26%
Revenue growth 5Y13.97%
Sales Q2Q%-71.54%
3.2 Future
ALVAL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.71% yearly.
Based on estimates for the next years, ALVAL will show a very strong growth in Revenue. The Revenue will grow by 361.83% on average per year.
EPS Next Y27.74%
EPS Next 2Y25.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year850%
Revenue Next 2Y565.23%
Revenue Next 3Y361.83%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ALVAL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALVAL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ALVAL's earnings are expected to grow with 25.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.71%
EPS Next 3YN/A
5. Dividend
5.1 Amount
ALVAL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:ALVAL (8/7/2025, 7:00:00 PM)
0.827
+0.02 (+3.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.25%
Inst Owner ChangeN/A
Ins Owners4.45%
Ins Owner ChangeN/A
Market Cap19.60M
Analysts85.45
Price Target3.35 (305.08%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.78%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-30.92%
Revenue NY rev (3m)-30.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 112 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.89 | ||
| P/tB | 2.12 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0.01
BVpS0.44
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.13% | ||
| ROE | -96.69% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-39.5%
ROA(5y)-33.42%
ROE(3y)-75.49%
ROE(5y)-68.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 44.46% | ||
| Cap/Sales | 149.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.04 | ||
| Quick Ratio | 2.66 | ||
| Altman-Z | 1.44 |
F-Score0
WACC7.07%
ROIC/WACCN/A
Cap/Depr(3y)37.28%
Cap/Depr(5y)37.7%
Cap/Sales(3y)63.68%
Cap/Sales(5y)68.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.15%
EPS Next Y27.74%
EPS Next 2Y25.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-96.3%
Revenue growth 3Y-16.26%
Revenue growth 5Y13.97%
Sales Q2Q%-71.54%
Revenue Next Year850%
Revenue Next 2Y565.23%
Revenue Next 3Y361.83%
Revenue Next 5YN/A
EBIT growth 1Y-45.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.13%
EBIT Next 3Y19.08%
EBIT Next 5Y24.99%
FCF growth 1Y-42.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.23%
OCF growth 3YN/A
OCF growth 5YN/A